Insider · CIK 0001623567
David Happel
Files at SGMT (Sagimet Biosciences Inc.). First filing Jul 23, 2025, latest Feb 12, 2026.
David Happel files SEC Form 4 as CEO, president and director at SGMT (Sagimet Biosciences Inc.). Since Jul 23, 2025, David Happel has reported 0 open-market buys worth $0 and 2 open-market sells worth $663k, the latest filed on Feb 12, 2026.
A track record needs three past buys with six months of prices behind them; David Happel has 0, so none is measured yet.
The newest scored trade: sold $65k of SGMT on Feb 10, 2026, filed Feb 12, 2026, scored 48 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $65k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SGMT: Sagimet Biosciences Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | Sagimet Biosciences Inc. | $65k 12,101 shares | -2% | +197% from low-45% from high | |
| 59Moderate | Sagimet Biosciences Inc. | $598k 65,478 shares | -9% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Jun 1, 2026 |
| Feb 19, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Series A Common Stock | +128,000 | $0.00 | $0 | 805,621 | Feb 20, 2026 |
| Feb 19, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +256,000 | $0.00 | $0 | 256,000 | Feb 20, 2026 |
| Feb 10, 2026 | SGMT Sagimet Biosciences Inc. | SOpen-market sale Series A Common Stock | -12,101 | $5.36 | $65k | 677,621 | Feb 12, 2026 |
| Jul 21, 2025 | SGMT Sagimet Biosciences Inc. | SOpen-market sale Series A Common Stock | -65,478 | $9.13 | $598k | 689,722 | Jul 23, 2025 |
| Feb 6, 2025 | SGMT Sagimet Biosciences Inc. | AGrant or award Series A Common Stock | +116,000 | $0.00 | $0 | 755,200 | Feb 7, 2025 |
| Feb 6, 2025 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +472,000 | $0.00 | $0 | 472,000 | Feb 7, 2025 |
Questions about David Happel
Answered from the filings on this page, as of the latest one.
Is David Happel buying or selling?
In the last 12 months David Happel reported 0 open-market buys worth $0 and 1 open-market sell worth $65k on SEC Form 4; the latest was sold $65k of SGMT on Feb 10, 2026. Grants, option exercises and tax withholding are not counted.
How did David Happel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Happel has 0.
Where does David Happel file Form 4?
David Happel has filed Form 4 at SGMT (Sagimet Biosciences Inc.) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.